For the first time, plutonium retention in human upper airways was investigated based on the dosimetric structure of the human respiratory tract proposed by the International Commission on Radiological Protection (ICRP). This paper describes analytical work methodology, case selection criteria, and summarizes findings on soluble (ICRP 68 Type M material) plutonium distribution in the lungs of a former nuclear worker occupationally exposed to plutonium nitrate [ 239 Pu(NO 3 ) 4 ]. Thirty-eight years post-intake, plutonium was found to be uniformly distributed between bronchial (BB), bronchiolar (bb) and alveolar-interstitial (AI) dosimetric compartments as well as between the left and right lungs.
INTRODUCTION
Deposition and retention of plutonium in anatomical regions of the human respiratory tract have been extensively studied (1) (2) (3) . However, investigation of plutonium distribution based on the dosimetric structure of the lungs proposed by the International Commission on Radiological Protection (ICRP) has not previously been attempted due to difficulties in tissue dissection. The dosimetric model's compartmental structure of the lung is different from its general anatomical structure represented by lobes: superior (upper), middle or lingular and inferior (lower) in the right lung and superior and inferior lobes in the left lung. From the dosimetry standpoint, the ICRP 66 human respiratory tract model (HRTM) divides the lungs into three compartments: (i) the bronchial region (BB), (ii) the bronchiolar region (bb) and (iii) the alveolar-interstitial region (AI) (4) . Each of the anatomical lobes contains tissues from all three dosimetric regions; thus, careful dissection of each lobe to separate BB, bb and AI tissues is crucial. Anatomically, BB tissues include trachea and bronchi (airway generations [1] [2] [3] [4] [5] [6] [7] [8] , bbbronchioles (airway generations 9-15) and AIrespiratory bronchioles (airway generation 16), alveolar ducts and sacks, alveoli, and interstitial tissue. Several decades post-exposure, plutonium activity concentrations in different lung tissues may vary significantly. This variation will depend on the solubility of the material and the extent of binding that may occur. Thus, incomplete dissection may cause cross-contamination leading to potentially incorrect results in plutonium activity concentration measurements, especially if tissue from a region with high activity is present in another. Measurement of plutonium activity concentrations in dosimetric regions of the lung provides important information on nuclide spatial distribution and permits characterization, both qualitatively and quantitatively, of plutonium binding to the airways. Bound material is expected to be diffusely distributed in all lung tissues, unlike localized 'particulate' aggregates. In the ICRP representation of binding, it is the dissolved ions and not undissolved particulates that are taken up to the bound state (4) . For this study, a USTUR whole-body donor (Case 0269) was selected. This individual was a Caucasian male involved in a single acute inhalation of acidic 239 Pu(NO 3 ) 4 solution in the form of an aerosol 'mist'. His estimated intake was~58 kBq. He was extensively treated with chelation therapy. The individual died from a malignant neoplasm of the prostate at the age of 79. A detailed description of this case was previously published (5) . It was determined that, 38 y post-intake, approximately 2% of total 239+240 Pu body activity still remained in the lungs. James et al. (5) concluded that long-term retention resulted from plutonium binding to lung tissues, with an estimated bound fraction (f b ) of 0.08. Microdistribution and long-term retention of plutonium material in the respiratory tract of this individual were previously studied using autoradiography technique (6) . Recently, carcinogenic and inflammatory effects of retained plutonium nitrate were also investigated using lung tissue samples from this case (7) . In the present study, the left lung from USTUR Case 0269 was dissected based on the ICRP 66 HRTM and radiochemically analyzed for plutonium isotopes. Alpha spectrometry (AS) was used for 239+240 Pu and 238 Pu activity measurements, and inductively coupled plasma mass spectrometry (ICP-MS) was used for measuring 240 Pu/ 239 Pu atom ratios and 241 Pu isotopic measurements. Distribution of retained plutonium material in the lungs was studied based on measured 239+240 Pu and 238 Pu activity concentrations. The results of this work provide key information on the extent of plutonium binding in the upper airways of the human respiratory tract (8) .
METHODS

Lung tissue dissection
Prior to the dissection, lung tissues were preserved in 10% buffered formalin. Formalin fixation forms protein cross-links within the tissues which aided in the dissection of the lung tissues with minimal crosscontamination.
A dissection protocol was developed that allows the separation of (i) BB tissue consisting of airway generations 1-8 and including big blood vessels, with very little if any contribution of AI tissue; (ii) bb tissue consisting of airway generations 9-14, with less than 1% contribution of AI tissue; (iii) AI tissue including white visceral pleura and terminal bronchioles-generation 15 (part of bb), which are too small to excise, and infiltrate along the pleura. A new set of surgical instruments were used for the dissection of each individual lung lobe to minimize cross-contamination.
A total of nine tissue samples including tissues from BB, bb and AI regions of the left lung, larynx, trachea, left bronchus, parabronchial lymph nodes (LNs), pulmonary LN and tracheobronchial LN were prepared for radiochemical analysis.
Tissue analysis
The actinide tissue analysis methods used at the USTUR were recently overviewed by Tolmachev et al. (9) Prior to radiochemical analysis, all samples were dry ashed at 450°C for 5 d, followed by wet ashing with a mixture of concentrated nitric acid (HNO 3 ) and hydrogen peroxide (H 2 O 2 ), and additional treatment with hydrofluoric acid (HF). After dry/wet ashing, sample ashes were dissolved in 6M hydrochloric acid (HCl), and the aliquots were taken from acid-digested tissue solutions (sample solutions) for further plutonium radiochemical analysis. From selected sample solution aliquots, plutonium was radiochemically separated from interfered radionuclides and sample matrix using vacuum-assisted extraction chromatography technique (10) . 242 Pu (NIST SRM-4334G) was used as a chemical recovery tracer. Actinide separation was performed with a tandem of 1-ml TEVA ® -DGA ® chromatographic resin cartridges on a vacuum box system (Eichrom Technologies, Darien, USA). For quality assurance and quality control (QA/QC) of the actinide separation, internal QA/QC samples (spiked with 240 Pu), method and reagent blanks (6M HCl) were prepared and analyzed along with the samples. After sequential thorium, uranium and americium removal, plutonium was eluted from TEVA ® resin, and purified plutonium fraction was submitted for electrodeposition. The electrodeposition technique was used to prepare α-counting source (planchet) for 239+240 Pu and 238 Pu activity measurement by AS (11) . Deposited 239+240 Pu and 238 Pu activities were measured using an Octête PLUS ® alpha spectroscopy system equipped with 450 mm 2 (active area) silicon surface barrier detectors (ORTEC, Oak Ridge, USA). AlphaVision ® (version 5.6.2) alpha spectrometry management software was used for data acquisition and handling. Prepared planchets and instrumental background were counted for 300 000 and 600 000 s, respectively. The average plutonium chemical recovery was 98.9 ± 6.0% (SD).
For mass-spectrometric analyses, 15-ml aliquots were taken from acid dissolved (6M HCl) tissue samples. Short-lived beta-emitter 
Plutonium distribution in lungs
Plutonium activity concentrations in the right and left side of the respiratory tract were found to be essentially identical. Right to left side weighted average 239+240 Pu concentration ratio was calculated to be 1.00 ± 0.01 for lung tissue and 1.02 ± 0.03 for LNs. For 238 Pu, the right to left side ratio was 0.87 ± 0.05 for the lungs and 0.89 ± 0.49 for LNs. Thus, in this case, plutonium distribution was uniform between the right and left sides of the respiratory tract (anatomical symmetry). 239+240 they were combined in a single pool for further statistical analysis. One sample t-test showed that the mean of these values was not significantly different from 1 (p = 0.148). This indicates that soluble plutonium material is uniformly distributed among bronchial, bronchiolar and alveolar-interstitial compartments (dosimetric symmetry).
Prior studies found that for particulate insoluble plutonium, the lowest plutonium concentration was in bronchial airways (BB) and the highest in bronchioles (bb) (1,2,) . In contrast to plutonium material distribution, plutonium activity among dosimetric compartments varied significantly with 22% retained in BB, 8% in bb and 70% in AI tissues. For particulate insoluble plutonium, about 78% of total activity was retained in parenchyma and parenchymal scar tissues (AI region) (1) . Table 3 summarizes the estimates of 239+240 Pu and 238 Pu retention in key body organs at the time of death along with the total systemic and whole-body activities.
Plutonium tissue content
Total
239+240
Pu activity in the lungs was estimated to be 24.8 ± 0.2 Bq, which is slightly lower than the previously published value of 26.7 Bq (5) . The latter was estimated based on radiochemical analysis of the right lung only. Total
Pu skeletal activity was re-evaluated using skeleton autopsy weight and weighted average 239+240 Pu concentration. The skeletal activity was estimated to be 1183 ± 4 Bq, which is in a good agreement with the published value of 1197 Bq (5) . Total systemic 239+240 Pu activity was estimated to be 2305 ± 23 Bq with 41% in the liver, 51% in the skeleton and 8% in other soft tissues. This is consistent with the ICRP 67 assumption that 90% of systemic plutonium is equally distributed between the liver and skeleton (12) .
Pu whole-body activity was estimated to be 2333 ± 23 Bq.
Soluble material intake confirmation
Radiochemical analysis confirmed that the individual was exposed to a soluble form of plutonium based on the following criteria: (i) thoracic LN to lung activity concentration ratio and (ii) liver to lung activity ratio. For inhalation of Type M material, thoracic LN to lung activity concentration ratio is expected to be approximately 1 (Bq kg
), while inhalation of ICRP 68 Type S material (representing insoluble forms of plutonium) results in a ratio greater than 19 (13) . Using
239+240
Pu weighted average concentration in the lungs and thoracic LNs, thoracic LN to lung activity concentration ratio was calculated to be 1.38 ± 0.02. Inhalation of Type S material results in liver to lung activity ratio (Bq Bq ) of approximately 1.6 at 10 000 d post-intake, while for inhalation of 'pure' Type M material or plutonium intake via wound, this ratio would be orders of magnitude higher (14) . Activity ratio was calculated to be 38 ± 1. These two criteria can be used (post-mortem) to identify cases where type of exposure was unknown.
CONCLUSION
For the first time, plutonium retention and distribution in the lungs of an occupationally exposed 
